Table A, Primers and probes for quantitative real-time PCR of ISGs and IFN-λs.

Table B, Clinical characteristics of chronic hepatitis C patients treated with PEG-IFN/RBV plus telaprevir or faldaprevir. Table C, Clinical characteristics of chronic hepatitis C patients according to IL28B genotype and treatment efficacy. Table D, Clinical characteristics of chronic hepatitis C patients treated with PEG-IFN/RBV. Figure A, Correlations between levels of mRNAs including suppressive genes at baseline. Figure B, Correlations between levels of mRNAs including suppressive genes at 24 hours after the initial administration PEG-IFN, RBV, plus NS3/4A protease inhibitor. Figure C, Correlation between levels of mRNA including suppressive genes and those for IL28B or ISG15 at 8 hours after the initial administration PEG-IFN, RBV, plus NS3/4A protease inhibitor. Figure D, Fold-changes of mRNAs for ISGs, TRIF and MAVS in PBMCs at 8, 24 hours relative to baseline in PEG-IFN/RBV and PEG-IFN/RBV/PI therapy. (PDF)